Amid Rising Infection Cases, Israel To Offer Third Pfizer-BioNTech COVID-19 Shot: CNBC

by Vandana Singh, Benzinga Editor

July 13, 2021 2:18 PM | 1 min read |

Israel will allow adults with severe pre-existing medical conditions to receive a third dose of the Pfizer Inc PFE - BioNTech SE BNTX COVID-19 vaccine, reports CNBC.
The decision comes amid a rise in infections rise due to the spread of the delta variant.
Israel’s health ministry said that the booster would be offered to adults considered to be at risk and specifically mentioned people with severe immunodeficiency or recently undergone an organ transplant.
Meanwhile, the debate continues as to whether a third dose of any vaccine is necessary.
Last week, Pfizer and BioNTech said they are developing a booster dose intended to target the delta variant.
Price Action: PFE shares are down 0.04% at $39.77, and BNTX shares are down 3.45% at $208.24 during the market session on the last check Tuesday.

Posted In: Biotech Government News Health Care FDA General Briefs CNBC

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.